Clinical Trials Logo
  1. Home
  2. Idiopathic Parkinson Disease
  3. NCT04202757

Intravenous Plasma Treatment for Parkinson's Disease — yFFP  

Idiopathic Parkinson Disease Clinical Trial

Official title:
Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease

Clinical Trial Summary

This study will do a preliminary evaluation of a possible treatment for mild-to-moderate Parkinson's disease. Patients will be treated with either transfusions of plasma from young donors. or with placebo transfusions. In the following several months, Parkinson's symptoms will be monitored and compared for the two groups.

Clinical Trial Description

This is a double-blind placebo controlled trial, designed to evaluate the efficacy of plasma from volunteer donors of ages 18-25. This young fresh frozen plasma (yFFP) will be given intravenously in two doses of 12.5 ml/kg each, with 40-56 hours between doses. In the following 24 weeks, Parkinson's symptoms will be monitored using the short version of the Stanford Presenteeism Scale (SPS-6), and a modified version of the UPDRS scale. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04202757
Study type Interventional
Source The Neurology Center
Contact
Status Completed
Phase Early Phase 1
Start date September 24, 2018
Completion date August 8, 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05103618 - Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA Phase 2
Completed NCT03700684 - Voice Treatment for Parkinson's Disease N/A
Completed NCT05027620 - Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology N/A
Completed NCT03652363 - GDNF in ideopathicParkinsons Disease Phase 2
Recruiting NCT02960464 - tDCS for Treatment of Depression in Parkinson's Disease N/A
Completed NCT05699161 - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson Phase 1/Phase 2
Completed NCT03944785 - Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Terminated NCT01215227 - An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) Phase 3
Withdrawn NCT05832775 - Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's Phase 1
Active, not recruiting NCT02780895 - Parkinsonian Brain Repair Using Human Stem Cells Phase 1
Recruiting NCT01860794 - Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease Phase 1/Phase 2
Terminated NCT02393027 - Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 Early Phase 1
Completed NCT02373072 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease Phase 1
Completed NCT02445651 - Physiological Effects of Nutritional Support in Patients With Parkinson's Disease N/A
Completed NCT00437125 - Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease Phase 4
Completed NCT02723396 - Sleep, Awake & Move - Part I
Completed NCT00599339 - Transdermal Rotigotine User Surveillance Study
Suspended NCT05471609 - Sustained Release Oral Formulation for Treatment of Parkinson's Disease Early Phase 1
Completed NCT00160576 - Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias Phase 2